XML 40 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2021
Mar. 29, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2021    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Document Transition Report false    
Document Annual Report true    
Entity Registrant Name Pyxis Oncology, Inc.    
Entity Central Index Key 0001782223    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period true    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity File Number 001-40881    
Entity Tax Identification Number 83-1160910    
Entity Address, Address Line One 35 Cambridgepark Drive    
Entity Address, City or Town Cambridge    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02140    
Entity Incorporation, State or Country Code DE    
City Area Code 617    
Local Phone Number 221-9059    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Trading Symbol PYXS    
Security Exchange Name NASDAQ    
Entity Public Float     $ 0
Entity Common Stock, Shares Outstanding   32,841,747  
Auditor Name Ernst & Young LLP    
Auditor Firm ID 42    
Auditor Location Boston, Massachusetts    
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrant’s Proxy Statement for its 2021 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2021.